VistaGen raises $3.75M for stem-cell derived drugs

August 10, 2007 | David P. Hamilton

South San Francisco, Calif.-based VistaGen Therapeutics, a biotech that uses human embryonic stem cells to discover new drugs, raised $3.75 million in a bridge financing as it prepares to raise up to $20 million in a fourth round. See our story in today’s briefing at VentureBeat Life Sciences.

Next Story: Biotech's double standard on biogenerics
Previous Story: Life sciences briefing: Friday, Aug. 10, 2007

Twitter

Facebook

Google Buzz

Digg

StumbleUpon

Delicious

Google

More...

About the Author, David P. Hamilton

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.